AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

In one study, the drug reduced blood levels of free PCSK9 protein by more than 90% from baseline when administered to healthy men as a single dose of between 10 and 300 mg, regardless of the dose ...

在全球血脂研究领域的最新报告中，截至1月16日15:59，共有282本期刊发布了447篇文章，其中涉及血脂相关的研究达到63篇，横跨20个科学领域，显示出血脂异常问题的普遍性和复杂性。 本期的焦点文章包括发表于《Frontiers in Nutrition》的《皱纹盘鲍生物活性肽作为高脂血症治疗潜在HMGCR抑制剂的虚拟筛选与评价》。研究显示，这种海洋生物提取物中的活性肽显示出显著的HMGCR抑制 ...

Statins: For statins, the side effects can be surprising. Some people taking these medications have been found to gain weight or body fat. There is also evidence that statins can lower testosterone ...

Both types are effective at managing cholesterol, but researchers have uncovered some surprising side effects. Weight Gain: ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

“We begin with drug-like non-natural cyclic peptides ... s publication regarding a new cyclic oral peptide inhibitor for PCSK9, a key regulator of LDL cholesterol and target for treating ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes ...

A variant of PCSK9, a gene involved in raising cholesterol, may spur metastasis. An approved antibody might stop it.

Reducing PCSK9 helps the liver remove more LDL from the blood. And the need for the drug is clear. For decades, statins — daily pills which reduce LDL levels by 30 to 50 per cent — have been ...